141 related articles for article (PubMed ID: 1396993)
1. Effect of aldose reductase inhibitor on the inhibition of platelet aggregation induced by diabetic rat plasma.
Takiguchi Y; Wada K; Nakashima M
Eur J Pharmacol; 1992 May; 215(2-3):289-91. PubMed ID: 1396993
[TBL] [Abstract][Full Text] [Related]
2. In vitro retinal and erythrocyte polyol pathway regulation by hormones and an aldose reductase inhibitor.
Hotta N; Kakuta H; Koh N; Fukasawa H; Yasuma T; Awaya S; Sakamoto N
Diabetes Res Clin Pract; 1991 Oct; 14(1):29-35. PubMed ID: 1748061
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
Sobajima H; Aoki T; Sassa H; Suzuki T; Taniko K; Makino M; Mizuno K; Suzuki T
Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994
[TBL] [Abstract][Full Text] [Related]
4. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats.
Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y; Terashima H; Morimura T; Tsuboshima M
Diabetologia; 1983 Apr; 24(4):290-2. PubMed ID: 6407887
[TBL] [Abstract][Full Text] [Related]
5. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.
Asano T; Saito Y; Kawakami M; Yamada N;
J Diabetes Complications; 2002; 16(2):133-8. PubMed ID: 12039395
[TBL] [Abstract][Full Text] [Related]
6. Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats.
Hotta N; Kakuta H; Fukasawa H; Kimura M; Koh N; Iida M; Terashima H; Morimura T; Sakamoto N
Diabetologia; 1985 Mar; 28(3):176-80. PubMed ID: 3922829
[TBL] [Abstract][Full Text] [Related]
7. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
Kashima K; Sato N; Sato K; Shimizu H; Mori M
Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
[TBL] [Abstract][Full Text] [Related]
8. Effects of a new aldose reductase inhibitor on various tissues in vitro.
Terashima H; Hama K; Yamamoto R; Tsuboshima M; Kikkawa R; Hatanaka I; Shigeta Y
J Pharmacol Exp Ther; 1984 Apr; 229(1):226-30. PubMed ID: 6423811
[TBL] [Abstract][Full Text] [Related]
9. Effects of aldose reductase inhibitor (ONO-2235) on human erythrocyte sorbitol concentrations in 75 g oral glucose tolerance tests.
Kamon N; Mabuchi H; Takeda R; Terashima H
Horm Metab Res; 1991 May; 23(5):226-9. PubMed ID: 1908433
[TBL] [Abstract][Full Text] [Related]
10. Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
Isogai S; Inokuchi T; Ohe K
Diabetes Res Clin Pract; 1995 Nov; 30(2):111-6. PubMed ID: 8833631
[TBL] [Abstract][Full Text] [Related]
11. Urinary sorbitol measurement and the effect of an aldose reductase inhibitor on its concentration in the diabetic state.
Nakano I; Tsugawa T; Shinohara R; Watanabe F; Fujita T; Nagata M; Kato T; Himeno Y; Kobayashi T; Fujiwara K; Nagata M; Itoh M; Nagasaka A
J Diabetes Complications; 2003; 17(6):337-42. PubMed ID: 14583178
[TBL] [Abstract][Full Text] [Related]
12. The role of sorbitol pathway and treatment effect of aldose reductase inhibitor ONO2235 in the up-regulation of cardiac M2-muscarinic receptors in streptozotocin-induced diabetic rats.
Liu TP; Juang SW; Cheng JT; Tong YC
Neurosci Lett; 2005 Jul 22-29; 383(1-2):131-5. PubMed ID: 15936525
[TBL] [Abstract][Full Text] [Related]
13. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
[TBL] [Abstract][Full Text] [Related]
14. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
15. Effects of ONO-2235, an aldose reductase inhibitor, on muscarinic receptors and contractile response of the urinary bladder in rats with streptozotocin-induced diabetes.
Kanda M; Eto K; Tanabe N; Sugiyama A; Hashimoto K; Ueno A
Jpn J Pharmacol; 1997 Mar; 73(3):221-8. PubMed ID: 9127817
[TBL] [Abstract][Full Text] [Related]
16. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y
Metabolism; 1984 Mar; 33(3):212-4. PubMed ID: 6420645
[TBL] [Abstract][Full Text] [Related]
17. Polyol pathway in tissues of spontaneously diabetic Chinese hamsters (Cricetulus griseus) and the effect of an aldose reductase inhibitor, ONO-2235.
Sekiguchi M; Watanabe K; Eto M; Iwashima Y; Morikawa A; Takahashi M; Ishii K; Makino I
Comp Biochem Physiol B; 1991; 98(4):637-40. PubMed ID: 1907900
[TBL] [Abstract][Full Text] [Related]
18. Effects of an aldose reductase inhibitor, ONO-2235, insulin and their combination on the altered responsiveness to the nerve stimulation and agonists of the isolated atria of diabetic rats.
Hashimoto H; Satoh N; Takiguchi Y; Nakashima M
J Pharmacol Exp Ther; 1990 May; 253(2):552-7. PubMed ID: 2159998
[TBL] [Abstract][Full Text] [Related]
19. Aldose reductase inhibitor ONO-2235 restores the alterations of bladder nerve growth factor and neurotrophin receptor p75 genetic expression in streptozotocin induced diabetic rats.
Tong YC; Cheng JT
J Urol; 2007 Nov; 178(5):2203-7. PubMed ID: 17870109
[TBL] [Abstract][Full Text] [Related]
20. Effects of aldose reductase inhibition with epalrestat on diabetes-induced changes in rat isolated atria.
Booth RJ; Hodgson WC
Clin Exp Pharmacol Physiol; 1993 Apr; 20(4):207-13. PubMed ID: 8485921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]